Cargando…

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations

Current acute myeloid leukemia (AML) disease models face severe limitations because most of them induce un-physiological gene expressions that do not represent conditions in AML patients and/or depend on external promoters for regulation of gene expression/repression. Furthermore, many AML models ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brabetz, Oliver, Alla, Vijay, Angenendt, Linus, Schliemann, Christoph, Berdel, Wolfgang E., Arteaga, Maria-Francisca, Mikesch, Jan-Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363507/ https://www.ncbi.nlm.nih.gov/pubmed/28325290 http://dx.doi.org/10.1016/j.omtn.2016.12.012

Ejemplares similares

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
por: Pohlmann, Alexander, et al.
Publicado: (2023)

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Berdel, Andrew F., et al.
Publicado: (2022)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells
por: Wenge, D V, et al.
Publicado: (2015)

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia
por: Wenge, Daniela V., et al.
Publicado: (2022)

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
por: Larrue, Clément, et al.
Publicado: (2021)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy
por: Ho, Tzu-Chieh, et al.
Publicado: (2021)

Chromosome engineering in zygotes with CRISPR/Cas9
por: Boroviak, Katharina, et al.
Publicado: (2016)

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
por: Lin, Steven, et al.
Publicado: (2014)

Applications of CRISPR-Cas9 mediated genome engineering
por: Yang, Xiao
Publicado: (2015)

Genome-Wide CRISPR-Cas9 Screen Identifies MicroRNAs That Regulate Myeloid Leukemia Cell Growth
por: Wallace, Jared, et al.
Publicado: (2016)

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
por: Li, Bin E., et al.
Publicado: (2023)

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
por: Brand, Caroline, et al.
Publicado: (2016)

CRISPR-Cas-Based Engineering of Probiotics
por: Liu, Ling, et al.
Publicado: (2023)

Optimization of Genome Engineering Approaches with the CRISPR/Cas9 System
por: Li, Kai, et al.
Publicado: (2014)

Engineered CRISPR-Cas9 nucleases with altered PAM specificities
por: Kleinstiver, Benjamin P., et al.
Publicado: (2015)

Optimization of genome editing through CRISPR-Cas9 engineering
por: Zhang, Jian-Hua, et al.
Publicado: (2016)

Low‐gluten, nontransgenic wheat engineered with CRISPR/Cas9
por: Sánchez‐León, Susana, et al.
Publicado: (2017)

Highly parallel genome variant engineering with CRISPR/Cas9
por: Sadhu, Meru J., et al.
Publicado: (2018)

Protein Engineering Strategies to Expand CRISPR-Cas9 Applications
por: Ribeiro, Lucas F., et al.
Publicado: (2018)

Optimization of T4 phage engineering via CRISPR/Cas9
por: Duong, Michelle M., et al.
Publicado: (2020)

Engineering large-scale chromosomal deletions by CRISPR-Cas9
por: Eleveld, Thomas F, et al.
Publicado: (2021)

CRISPR-Cas9 delivery strategies with engineered extracellular vesicles
por: Lu, Yaoyao, et al.
Publicado: (2023)

A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity
por: Barghout, Samir H., et al.
Publicado: (2021)

Efficient Genome Engineering of Toxoplasma gondii Using CRISPR/Cas9
por: Sidik, Saima M., et al.
Publicado: (2014)

Genome Engineering of Drosophila with the CRISPR RNA-Guided Cas9 Nuclease
por: Gratz, Scott J., et al.
Publicado: (2013)

Heritable Multiplex Genetic Engineering in Rats Using CRISPR/Cas9
por: Ma, Yuanwu, et al.
Publicado: (2014)

A CRISPR-Cas9 System for Genetic Engineering of Filamentous Fungi
por: Nødvig, Christina S., et al.
Publicado: (2015)

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
por: Maddalo, Danilo, et al.
Publicado: (2014)

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression
por: Osborn, Mark J., et al.
Publicado: (2018)

CRISPR-Cas9 In Situ engineering of subtilisin E in Bacillus subtilis
por: Price, Marcus A., et al.
Publicado: (2019)

CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
por: Lone, Bilal Ahmad, et al.
Publicado: (2018)

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
por: Oakes, Benjamin L, et al.
Publicado: (2016)

CRISPR/Cas9 Immune System as a Tool for Genome Engineering
por: Hryhorowicz, Magdalena, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i85042lbc4lqim4g8bq5370q0o